Pharma Equity Group

0.10 DKK

-0.99 %

Less than 1K followers

PEG

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

-0.99 %

+1.52 %

-27.44 %

-11.84 %

-47.11 %

-43.70 %

-77.67 %

-78.90 %

-99.61 %

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Market cap

123.37M DKK

Turnover

22.29K DKK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Coverage

Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 10.09.2025

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All

Research

Webcasts

Press releases

3rd party

ShowingAll content types

Pharma Equity Group (PEG) - Signs Letter of Intent (LOI) to acquire MedTech company Otiom

Analyst Comment12/10/2025, 12:31 PM by

Pharma Equity Group (PEG) - Signs Letter of Intent (LOI) to acquire MedTech company Otiom

Pharma Equity Group (PEG) has taken the first tangible step in executing its diversification strategy announced in May 2025 by signing a Letter of Intent (LOI) to acquire Otiom A/S, a Danish MedTech company specializing in IoT-based localization technology for people with dementia. The transaction marks PEG’s initial expansion beyond pharmaceuticals into commercial-stage MedTech and aligns with CEO Christian Tange’s (new CEO from 1 April 2025) ambition to become a Nordic life sciences consolidator.

Pharma Equity Group

Regulatory press release12/10/2025, 11:17 AM

Pharma Equity Group eksekverer på selskabets nye strategi: Indgår hensigtserklæring om opkøb af MedTech-virksomheden Otiom A/S

Pharma Equity Group

Regulatory press release12/10/2025, 11:17 AM

Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S

Pharma Equity Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/3/2025, 7:19 AM

Pharma Equity Group A/S aftale med Danske Bank som liquidity provider ophører 1. januar 2026

Pharma Equity Group

Regulatory press release12/3/2025, 7:19 AM

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Pharma Equity Group

Regulatory press release12/1/2025, 12:10 PM

Bestyrelsens beslutning om udstedelse af konvertible lån

Pharma Equity Group

Regulatory press release12/1/2025, 12:10 PM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group

Dagens aktienyheder 27/11-2025: Pharma Equity Group A/S (PEG), Curasight og Vestjysk Bank

Analyst Comment11/27/2025, 8:05 AM by

Dagens aktienyheder 27/11-2025: Pharma Equity Group A/S (PEG), Curasight og Vestjysk Bank

Dagens aktienyheder med Pharma Equity Group A/S (PEG), Curasight og Vestjysk Bank

Pharma Equity Group Curasight Vestjysk Bank

Regulatory press release11/26/2025, 3:40 PM

Corrective information regarding the Annual Report 2024 and the Interim Report for H1 2025 following an order from the Danish Business Authority

Pharma Equity Group

Regulatory press release11/26/2025, 3:40 PM

Korrigerende information til årsrapporten 2024 samt delårsrapporten for 1. halvår 2025 som følge af påbud fra Erhvervsstyrelsen

Pharma Equity Group

Pharma Equity Group: PEG restrukturerer gæld gennem nye konvertible lån

Analyst Comment10/2/2025, 11:56 AM by

Pharma Equity Group: PEG restrukturerer gæld gennem nye konvertible lån

Pharma Equity Group har konsolideret sin finansieringsstruktur ved at udstede nye konvertible lån på DKK 10,9 mio. den 1. oktober 2025, hvorved de tidligere lån fra april og juli 2025 samt en udnyttet kreditfacilitet refinansieres. Det nye konvertible lån har samme årlige rente på 10% som udstedelsen i juli 2025, men udvider konverteringsvinduet, der nu åbner om 23 måneder (september 2027).

Pharma Equity Group

Regulatory press release10/1/2025, 7:24 AM

Bestyrelsens beslutning om udstedelse af konvertible lån

Pharma Equity Group

Regulatory press release10/1/2025, 7:24 AM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group

Pharma Equity Group: Video med præsentation af Reponex pipeline

Analyst Comment9/10/2025, 1:55 PM by

Pharma Equity Group: Video med præsentation af Reponex pipeline

Efter myndighedsgodkendelsen til fase 2-studiet med RNX-011(livstruende bughindebetændelse) vil Reponex direktør Sebastian Bo Jakobsen gennemgår næste fase af studiet og hvad godkendelsen indebærer. Derudover vil CEO i Pharma Equity Group Christian Tange gennemgå kommercialiseringsmulighederne for RNX-011.

Pharma Equity Group

Pharma Equity Group – Præsentation af vigtig milepæl for datterselskabet Reponex

Webcast9/10/2025, 8:30 AM

Pharma Equity Group – Præsentation af vigtig milepæl for datterselskabet Reponex

Mød og stil spørgsmål til Reponex CEO Sebastian Bo Jakobsen og Pharma Equity Group CEO Christian Tange onsdag den 10. september kl. 10.30.

Pharma Equity Group

Dagens aktienyheder 10/09: GreenMobility A/S, GrønlandsBANKEN og Pharma Equity Group A/S (PEG

Analyst Comment9/10/2025, 7:03 AM by

Dagens aktienyheder 10/09: GreenMobility A/S, GrønlandsBANKEN og Pharma Equity Group A/S (PEG

Dagens aktienyheder med GreenMobility A/S, GrønlandsBANKEN og Pharma Equity Group A/S (PEG

GreenMobility Grønlandsbanken Pharma Equity Group

Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point

Research9/10/2025, 6:31 AM by

Claus Thestrup, Philip Coombes

Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point

PEG maintained its guidance with its H1 2025 results, for DKK 11m in partner-driven revenue. The recent approval to initiate its RNX- 011 Phase IIb clinical trial strengthens PEG’s partner negotiation position.

Pharma Equity Group

Mød ledelsen i Pharma Equity Group (PEG) og GreenMobility og stil spørgsmål i dagens investorpræsentationer

Analyst Comment9/10/2025, 6:00 AM

Mød ledelsen i Pharma Equity Group (PEG) og GreenMobility og stil spørgsmål i dagens investorpræsentationer

Mød ledelsen i Pharma Equity Group (PEG) og GreenMobility og stil spørgsmål i dagens investorpræsentationer

Pharma Equity Group GreenMobility

Regulatory press release9/2/2025, 8:03 AM

Korrektion: Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, har fået myndighedsgodkendelse til at igangsætte afgørende klinisk studie med RNX-011 til livstruende peritonitis

Pharma Equity Group

Regulatory press release9/2/2025, 8:03 AM

Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.